Home Page

 
Diabetes Pgm 2018 Voxmedia Program Image



         Diabetes Therapies and Cardiovascular Risk Reduction:
         Taking a Closer Look at SGLT2 Inhibitors and GLP-1
         Receptor Agonists

          Tuesday, October 9, 2018

         New Orleans Downtown Marriott at the Convention Center
         Blaine Kern Ballroom
         859 Convention Center Boulevard
         New Orleans, Louisiana

         Dinner & Registration: 6:00 pm - 6:30 pm
         Symposium:  6:30 pm - 8:00 pm

Registration for this program is now closed.

 
Faculty:  Jay Shubrook, DO, FAAFP (Chair); Lawrence Leiter, MD; Darren McGuire, MD, MHSc
Program Overview:

In this program, an expert faculty (Chair Dr. Jay Shubrook, Dr. Lawrence Leiter, and Dr. Darren McGuire) will discuss the new recommendations for management of hyperglycemia, the roles for SGLT2 inhibitors and GLP-1 RAs, and the importance of identifying atherosclerotic cardiovascular disease (ASCVD) for consideration of diabetes drugs. The numerous recently completed CVOTs and large multinational studies with these therapies will be interpreted. Best practices for using these agents will be demonstrated using case studies and explained with take-home tips for clinical practice.

Educational Objectives: 
Upon completion of this program, attendees should be able to:

  • Indicate recommendations for use of GLP-1 RAs and SGLT2 inhibitors
  • Discuss the glycemic efficacy and safety profiles of SGLT2 inhibitors and GLP-1 receptor agonists.
  • Identify the metabolic and renal effects of SGLT2 inhibitors and GLP- 1 receptor agonists.
  • Interpret the results of studies evaluating the effects of SGLT2 inhibitors and GLP-1 receptor agonists on the risk for major adverse cardiovascular outcomes.
  •  

    Free CME Here

    Target Audience:  This program was developed for the education of family physicians and other healthcare professionals.

    Accreditation & Credit Designation Statements:
    This Live activity, Diabetes Therapies and Cardiovascular Risk Reduction: Taking a Closer Look at SGLT2 Inhibitors and GLP-1 Receptor Agonists, with a beginning date of 10/09/2018, has been reviewed and is acceptable for up to 1.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Voxmedia LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    Voxmedia LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 CreditsTM through its reciprocity agreements.
    The National Commission on Certification of Physician Assistants accepts AMA PRA Category 1 CreditsTM from organizations accredited by the ACCME.

    Educational Grant: Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals LP.